For instance, the potential effect of Riluzole and Edaravone, two FDA approved drugs for amyotrophic lateral sclerosis (ALS), that are known to play a key role in regards to the stabilization and structural deviations of the mutant profilin-1 gene (PFN-1) is assessed by in silico tools. The gene discussed is PFN1; the disease is amyotrophic lateral sclerosis.